Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603889 · ClinicalTrials.gov registry record · NA
Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
A NA study, sponsored by Albert B. Sabin Vaccine Institute.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00603889: Completed NA study, sponsored by Albert B. Sabin Vaccine Institute.
NCT00603889 is a NA study that has completed, run by Albert B. Sabin Vaccine Institute. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00603889, a NA study, has completed, sponsored by Albert B. Sabin Vaccine Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset of volunteers. This study will evaluate solutions of varying concentrations of the protein in both a skin prick-puncture and intradermal test that will eventually be used to screen volunteers living in hookworm endemic areas who are being considered as potential participants in vaccine trials, to reduce the potential of inducing allergic reactions in those vaccinated with the Na-ASP-2 Hookworm Vaccine.
Primary Outcome
Mean grade of wheal reaction after 2 applications of the skin test reagent per participant. For each skin test reaction, the grade of the test was determined based on the mean of the longest and orthogonal diameters, which was then compared to the equivalent measurements of a histamine solution positive control that was applied at the same time as the test. Grading was as follows: 0 no discernible wheal 1. \< ½ histamine diameter 2. ≥ ½ histamine; \< histamine diameter 3. = size of histamine c
Interventions
- BIOLOGICAL Na-ASP-2 Skin Test Reagent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-05 |
| Phase | NA |
What the finished NCT00603889 record still lists
NCT00603889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Na-ASP-2 Skin Test Reagent is the first listed.
NCT00603889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00603889 about?
NCT00603889 is a clinical study titled "Development of a Skin Test for the Na-ASP-2 Hookworm Antigen". Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset of volunteers. This study will evaluate solutions of varying concentrat...
What is the current status of trial NCT00603889?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2008-03. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00603889?
The interventions under investigation include: Na-ASP-2 Skin Test Reagent (BIOLOGICAL).
Who is sponsoring clinical trial NCT00603889?
This trial is sponsored by Albert B. Sabin Vaccine Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00603889's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia